Private company

F-star Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. We are pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. We have four second generation immuno-oncology (also referred to as "IO") therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137.”57 It is headquartered in Cambridge, United Kingdom.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge, United Kingdom1
  • Incorporated inDE2
  • Business address35 Parkwood Drive, Babraham Research Campus, Cambridge, X0 Cb22 3At2
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-145.1%Operating margin3
-147.8%Net margin3
88.1%Revenue growth, 20213
-32.3%Return on equity3
0.10×Debt to equity3
-$27.9MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development96¢$28.8M
  • Interest3¢$844.0K
  • Income tax1¢$372.0K

Out of $21.2M in revenue.3 The company lost money this year.

Financial statements

Revenue43$21.2M in 2021−25% since 2019
0$10.0M$20.0M$30.0M2019: $28.3M$28.3M20192020: $11.3M$11.3M2020−60%2021: $21.2M$21.2M2021+88%
Operating income567843-$30.7M in 2021+165% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$11.6M-$11.6M20152016: -$19.4M-$19.4M2016+67%2017: -$21.3M-$21.3M2017+10%2018: -$28.5M-$28.5M2018+34%2019: -$22.5M-$22.5M2019−21%2020: -$22.4M-$22.4M2020−0%2021: -$30.7M-$30.7M2021+37%
Net income567843-$31.3M in 2021+171% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$11.6M-$11.6M20152016: -$17.4M-$17.4M2016+50%2017: -$27.7M-$27.7M2017+59%2018: -$22.9M-$22.9M2018−17%2019: -$23.0M-$23.0M2019+1%2020: -$25.6M-$25.6M2020+11%2021: -$31.3M-$31.3M2021+22%
Fiscal year2015201620172018201920202021
Revenue$28.3M4$11.3M3$21.2M3
Research and development$7.5M5$14.0M6$13.1M7$19.8M8$31.4M4$14.1M3$28.8M3
Operating expenses$51.9M3
Operating income-$11.6M5-$19.4M6-$21.3M7-$28.5M8-$22.5M4-$22.4M3-$30.7M3
Interest$542.0K8$1.0M3$844.0K3
Income before tax-$31.7M3
Income tax$06$06$07-$737.0K4-$1.0K3-$372.0K3
Net income-$11.6M5-$17.4M6-$27.7M7-$22.9M8-$23.0M4-$25.6M3-$31.3M3
Earnings per share-$2.487-$1.598-$1.468
Earnings per share (diluted)-$2.487-$1.888-$1.468

Compare F-star Therapeutics, Inc. with another company

Corporate structure

F-star Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of F-star Therapeutics, Inc.

  • Beryl Capital Management LLC Filed SC 13G on F-star Therapeutics, Inc., latest Mar 17, 2023
  • Ridgeback Capital Investments L.P. Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 14, 2023 (3 filings since Feb 14, 2022)
  • Rock Springs Capital Management LP Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 15, 2022
  • Atlas Venture Opportunity Fund I, L.P. Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 14, 2022
  • Boxer Capital, LLC Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 14, 2022
  • Point72 Asset Management, L.P. Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 14, 2022
  • Kgaa Merck Filed SC 13G/A on F-star Therapeutics, Inc., latest Feb 8, 2022
  • F-star Therapeutics, Inc. Cambridge, United Kingdom

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What F-star Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.5M3 Dec 31, 2021$2.0M3 Dec 31, 2020+29.0%
Accumulated depreciation$1.7M3 Dec 31, 2021$1.2M3 Dec 31, 2020+40.0%
Property and equipment, net$887.0K3 Dec 31, 2021$789.0K3 Dec 31, 2020+12.4%
Operating-lease assets (leased space)$3.3M3 Dec 31, 2021$2.8M3 Dec 31, 2020+17.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$78.5M3 Dec 31, 2021$18.5M3 Dec 31, 2020+324.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$14.9M3 Dec 31, 2021$14.9M3 Dec 31, 2020−0.2%
Intangible assets, net (excluding goodwill)$18.8M3 Dec 31, 2021$19.0M3 Dec 31, 2020−1.2%
Indefinite-lived intangibles (excluding goodwill)$19.0M4 Dec 31, 2020$13.0M4 Dec 31, 2019+45.5%
Finite-lived intangibles, gross$4.5M3 Dec 31, 2021
Finite-lived intangibles, net$4.3M3 Dec 31, 2021

Leadership

Who has led F-star Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Martin J. Driscoll2016–2020
  2. Eliot Forster2020–2023

President

  1. Martin J. Driscoll2016–2020
  2. Eliot Forster2020–2023

Chief financial officer

  1. Jonathan Freve2016–2020
  2. Darlene M. Deptula-Hicks2020–2022
20202025
Board members and other officers (20)

Former names

  • Spring Bank Pharmaceuticals, Inc.Jan 25, 2013 to Nov 9, 20202

Timeline

  1. Mar 9, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights33
  2. Mar 7, 20238-K Other events34
  3. Mar 6, 20238-K Entered a material agreement; Other events35
  4. Feb 23, 20238-K Entered a material agreement; Other events36
  5. Feb 9, 20238-K Entered a material agreement; Other events37
  6. Feb 1, 20238-K Entered a material agreement; Other events38
  7. Dec 30, 20228-K Entered a material agreement; Other events39
  8. Dec 29, 20228-K Other events40
  9. Dec 21, 20228-K Entered a material agreement; Other events41
  10. Dec 19, 20228-K Entered a material agreement; Other events42
  11. Nov 21, 20228-K Entered a material agreement; Other events43
  12. Nov 1, 20228-K Other events44
  13. Nov 24, 2020New chief executive Eliot Forster becomes CEO12
  14. May 5, 2016New chief executive Martin J. Driscoll becomes CEO13

Calendar

When it reported results

  1. Aug 11, 2022Reported quarterly or annual results45
  2. May 10, 2022Reported quarterly or annual results46
  3. Mar 14, 2022Reported quarterly or annual results47
  4. Nov 10, 2021Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

133 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 21 major events, 29 insider forms, 9 large holders, 66 other. The latest 20:

  1. Mar 20, 202315-12G TERMINATION OF REGISTRATION EDGAR
  2. Mar 17, 2023SC 13G EDGAR
  3. Mar 13, 2023EFFECT EDGAR
  4. Mar 13, 2023EFFECT EDGAR
  5. Mar 13, 2023EFFECT EDGAR
  6. Mar 13, 2023EFFECT EDGAR
  7. Mar 13, 2023EFFECT EDGAR
  8. Mar 9, 2023S-8 POS EDGAR
  9. Mar 9, 2023S-8 POS EDGAR
  10. Mar 9, 2023S-8 POS EDGAR
  11. Mar 9, 2023S-8 POS EDGAR
  12. Mar 9, 2023S-8 POS EDGAR
  13. Mar 9, 2023S-8 POS EDGAR
  14. Mar 9, 2023POS AM EDGAR
  15. Mar 9, 2023POS AM EDGAR
  16. Mar 9, 2023POS AM EDGAR
  17. Mar 9, 2023POS AM EDGAR
  18. Mar 9, 2023POS AM EDGAR
  19. Mar 9, 20238-K EDGAR
  20. Mar 9, 2023SC 14D9/A EDGAR

The 133 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 2, 2021Kayitalire LouisCHIEF MEDICAL OFFICERSale64$6.83$437Form 4
Oct 4, 2021Kayitalire LouisCHIEF MEDICAL OFFICERSale64$7.23$463Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How F-star Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARF-star Therapeutics, Inc.1
  • CIK0001566373
  • Employer ID (EIN)52-23863451
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address35 Parkwood Drive, Babraham Research Campus, Cambridge, X0 CB22 3AT1
  • Phone44 1223 4974001
  • Shares outstanding21,981,919 as of Sep 30, 202211
  • Public float$176.8M as of Dec 31, 202156
  • On EDGAR sinceJan 25, 20131
  • Filings522 in all: 4 (193), 8-K (73), 3 (23), SC 13G/A (22), 10-Q (21), SC 14D9/A (19), SC TO-T/A (19), SC 13G (15)1
    All 47 form types

    CORRESP (14), EFFECT (14), UPLOAD (9), 424B5 (8), POS AM (8), DEF 14A (7), S-8 POS (7), 10-K (6), DEFA14A (6), S-8 (6), 4/A (5), 425 (5), D (4), S-1/A (4), S-3 (4), 10-Q/A (3), 10-K/A (2), CT ORDER (2), S-1 (2), SC14D9C (2), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), S-3/A (1), S-4 (1), S-4/A (1), SC 13D (1), SC 13D/A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 15, 2022
    Quarterly report (10-Q) Nov 10, 2022
    Proxy statement (DEF 14A) Apr 22, 2022
    Latest 8-K (8-K) Mar 9, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57